Ascentage Pharma announced that it has released updated data from a US study of the company’s novel drug candidate, olverembatinib, in patients with refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, in a Poster Presentation at the 65th American Society of Hematology Annual Meeting, taking place in San Diego, CA, the United States.
